Total IgE, eosinophils, and interleukins 16, 17A, and 23 correlations in severe bullous pemphigoid and treatment implications.
IL-16
IL-17A
IL-23
IgE
bullous pemphigoid
eosinophils
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
17
05
2020
revised:
15
06
2020
accepted:
30
06
2020
pubmed:
6
7
2020
medline:
15
5
2021
entrez:
5
7
2020
Statut:
ppublish
Résumé
Bullous pemphigoid (BP) patients are predominantly above 70 years of age, with limited tolerance to the side effects of the immunosuppressive drugs. Advancements in our understanding of the pathophysiology of BP have led to the development of molecules which target specific pathways involved in induction and perpetuation of disease. Patients with BP Disease Area Index above 60 and less than 100 were split into two groups-one with high and the other with normal levels of IgE. The tested parameters included eosinophils' count, total IgE serum level, and interleukins (IL) 16, 17A, and 23 counts in the peripheral blood and skin bulla serum, before any therapeutic intervention. Thirty individuals fulfilled the criteria for enrollment. Patients with high IgE blood serum levels had significantly higher levels of IL17A and normal IL23 levels in blood and bulla serum. Patients with normal serum IgE levels had slightly higher IL23 levels in blood and bulla serum. The eosinophil count was positively related to IL17 blood serum level and negatively related to IL23. IL16 did not differ in the two groups. BP patients may represent a group of patients benefiting most substantially from the introduction of nonimmunosuppressive therapeutics into the treatment regimens for their disease. Clinical criteria and immune biomarkers are needed for making the best therapeutic choice.
Substances chimiques
Interleukin-16
0
Interleukins
0
Immunoglobulin E
37341-29-0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13958Informations de copyright
© 2020 Wiley Periodicals LLC.
Références
Colbert RL, Allen DM, Eastwood D, Fairley JA. Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol. 2004;122:1091-1095.
Kasperkiewics M, Zillikens D, Schmidt E. Pemphigoid diseases: pathogenesis, diagnosis, and treatment. Autoimmunity. 2012;45:55-70.
Schmidt E, Zillikens D. Pemphigoid disease. Lancet. 2013;381:320-332.
Oh DD, Zhao CY, Murrell DF. A review of case-control studies on the risk factors for the development of autoimmune blistering diseases. J Eur Acad Dermatol Venereol. 2016;30:595-603.
Jordon RE, Beutner EH, Witebsky E, Blumental G, Hale WL, Lever WF. Basement zone antibodies in bullous pemphigoid. JAMA. 1967;200:751-756.
Petrera MR, Tampoia M, Guida S, Abbracciavento L, Fumarulo R, Foti C. Bullous pemphigoid and neurologic diseases: toward a specific serologic profile? Endocr Metab Immune Disord Drug Targets. 2018;18:662-664.
Molina EG, Yanovsky RL, Wei XE, Chen TS. Missed drug-induced bullous pemphigoid leads to longer immunosuppression than recognized cases: a 9-year retrospective review. 2020; 82: 1255-8.
Lin L, Hwang BJ, Culton DA, et al. Eosinophils mediate tissue injury in autoimmune skin disease bullous pemphigoid. J Invest Dermatol. 2018;138:1032-1043.
Plee J, Le Jan S, Giustiniani J, et al. Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies variation, contributes to predict bullous pemphigoid outcome. Sci Rep. 2015;14:18001.
Chakievska L, Holtsche MM, Kunster A, et al. IL-17A is a functionally relevant and a potential therapeutic target in BP. J Autoimm. 2019;19:104-112.
Giusti D, Bini E, Terryn C, et al. NET formation in bullous pemphigoid patients with relapse is modulated by IL-17 and IL-23 interplay. Front Immunol. 2019;10:701.
Holtsche MM, Goletz S, van Beek N, et al. Prospective study in bullous pemphigoid: association of high serum anti-BP180 IgG levels with increased mortality and reduced Karnofsky score. Br J Dermatol. 2018;179:918-924.
Wijayanti A, Cy Z, Boettiger D, et al. The reliability, validity and responsiveness of two diseases scores (BPDAI and ABSIS) for bullous pemphigoid: which one to use? Acta Dermatol Venereol. 2017;97:24-31.
Saniklidou HA, Tighe PJ, Fairclough LC, Todd I. IgE autoantibodies and their association with the disease activity and phenotype in bullous pemphigoid: a systematic review. Arch Dermatol Res. 2018;310:11-28.
Frezzolini A, Cianchini G, Ruffelli M, Cadoni S, Puddu P, De Pità O. Interleukin-16 expression and release in bullous pemphigoid. Clin Exp Dermatol. 2004;137:595-300.
Li Y, Zhu L, Chu Z, et al. Characterization and biological significance of IL-23-induced neutrophil polarization. Cell Mol Immunol. 2018;15:518-530.
Seyed Jafari SM, Gadaldi K, Feldmeyer L, Yawalkar N, Borradori L, Schlapbach C. Effects of omalizumab on FcεRI and IgE expression in lesional skin of bullous pemphigoid. Front Immunol. 2019;10:1-6.
Cozzani E, Gasparini G, Di Zenzo G, Parodi A. Immunoglobulin E and bullous pemphigoid. EurJDermatol. 2018;28:440-448.
Kowalski EH, Kneibner D, Kridin K, Amber KT. Serum and blister fluid levels of cytokines and chemokines in pemphigus and bullous pemphigoid. Autoimmun Rev. 2019;18:526-534.
Messingham KN, Holahan HM, Frydman AS, Fullenkamp C, Srikantha R, Fairley JA. Human eosinophils express the high affinity IgE receptor, FcεRI, in bullous pemphigoid. PLoS. 2014;9:e107725.
Van Beek N, Lüttmann N, Huebner F, et al. Correlation of serum levels of IgE autoantibodies against BP180 with bullous pemphigoid disease activity. JAMA Dermatol. 2017;153:30-38.
Van Beek N, Schulze FS, Zillikens D, Schmidt E. IgE-mediated mechanisms in bullous pemphigoid and other autoimmune bullous diseases. Expert Rev Clin Immunol. 2016;12:267-277.
Dressow SK, Sitaru C, Recke A, Oostingh GJ, Zillikens D, Gibbs BF. IgE autoantibodies against the intracellular domain of BP180. Br J Dermatol. 2009;160:429-432.
Zuo Y, Evangelista F, Culton D, et al. IgG4 autoantibodies are inhibitory in the autoimmune disease bullous pemphigoid. J Autoimm. 2016;73:111-119.
McFadden C, Morgan R, Rahangdale S, et al. Preferential migration of T regulatory cells induced by IL-16. J Immunol. 2007;179:6439-6445.
Furukawa F, Kumagai S, Sakamoto Y, Takigawa M, Imamura S. Elevated serum levels of IgE-binding factor/soluble sCD23 in bullous pemphigoid. J Dermatol Sci. 1994;7:150-154.
Schmidt E, Brocker EB, Zillikens D. High levels of soluble CD23 in blister fluid of patients with bullous pemphigoid. Arch Dermatol. 1995;131:966-967.
Inaoki M, Sato S, Takehara K. Elevated expression of CD23 on peripheral blood B lymphocytes from patients with bullous pemphigoid: correlation with increased serum IgE. J Dermatol Sci. 2004;35:53-59.
Ettinger R, Karnell JL, Henault J, et al. Pathogenic mechanisms of IgE-mediated inflammation in self-destructive autoimmune responses. Autoimmunity. 2017;50:25-36.
Messingham KN, Srikantha R, DeGueme AM, Fairley JA. FcR-independent effects of IgE and IgG autoantibodies in bullous pemphigoid. J Immunol. 2011;187:553-560.
Jones BE, Maerz MD, Buckner JH. IL-6: a cytokine at the crossroads of autoimmunity. Curr Opin Immunol. 2018;55:9-14.
Kikuchi I, Kikuchi S, Kobayashi T, et al. Eosinophil trans-basement membrane migration induced by interleukin-8 and neutrophils. Am J Resp Cell Mol Biol. 2006;34:760-765.